Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year Low – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR) reached a new 52-week low on Friday . The stock traded as low as $25.74 and last traded at $25.80, with a volume of 324671 shares changing hands. The stock had previously closed at $27.04.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 price target on the stock. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Down 6.6 %

The company’s 50-day moving average is $32.03 and its 200-day moving average is $36.48. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -34.13 and a beta of -2.78.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $1,064,000. Vestal Point Capital LP boosted its position in shares of Structure Therapeutics by 105.4% during the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after buying an additional 590,000 shares during the period. Lighthouse Investment Partners LLC acquired a new stake in shares of Structure Therapeutics in the second quarter valued at $1,178,000. abrdn plc raised its holdings in shares of Structure Therapeutics by 132.7% in the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares during the period. Finally, Barclays PLC lifted its stake in Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after acquiring an additional 31,815 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.